PKC412 in treatment of atypical chronic myeloid leukemia

摘要

The present invention relates to the use of STAUROSPORINES DERIVATIVES for the preparation of a drug for the treatment of diseases involving SPTBN1-FLT3 translocation- modulated signalling pathways and / or SPTBN 1-FLT3 translocation gene product, especially for the curative and/or prophylactic treatment of myeloid leukemia, including especially atypical chronic myeloid leukemia, and to a method of treating diseases involving SPTBN1-FLT3 translocation-modulated signalling pathways and / or SPTBN1-FLT3 translocation gene product.